IV-01 Christiane Dings Mathematical modeling of the oral glucose tolerance test in pre-diabetic patients: An IMI DIRECT study Thursday 15:25-16:50 |
IV-02 Anne-Gaelle Dosne Exposure-response analysis of erdafitinib and pharmacodynamic-guided dose individualization in patients with locally advanced or metastatic urothelial carcinoma Thursday 15:25-16:50 |
IV-03 Erwin Dreesen A population pharmacokinetic and exposure-response model to support therapeutic drug monitoring during vedolizumab induction therapy Thursday 15:25-16:50 |
IV-04 Ronan Duchesne Identifiability in nonlinear mixed effect models: the example of in vitro erythropoiesis Thursday 15:25-16:50 |
IV-05 Vincent Duval A continuous-time Markov model (CTMM) for investigator’s global assessment (IGA) score in moderate-to-severe atopic dermatitis treated with subcutaneous nemolizumab. Thursday 15:25-16:50 |
IV-06 Dimitra Eleftheriadou Aluminium biokinetics: Elucidating the speciation kinetics of the aluminium-citrate system in vitro. Thursday 15:25-16:50 |
IV-07 Douglas J. Eleveld Aging and maturation as a reliability problem: The Weibull distribution and age- and maturation-adjustment functions Thursday 15:25-16:50 |
IV-08 Esther Encinas Use of modeling and simulation methods to support the generic application of a vaginal delivery system Thursday 15:25-16:50 |
IV-09 Aline Engbers Postnatal age, gestational age and small for gestational age drive the pharmacokinetics of ibuprofen enantiomers in very preterm neonates with patent ductus arteriosus Thursday 15:25-16:50 |
IV-10 Muhammad Faisal Simultaneous semi-mechanistic population pharmacokinetic analysis of enalapril and enalaprilat in serum and urine following the administration of child appropriate oro-dispersible mini-tablets. Thursday 15:25-16:50 |
IV-11 Undine Falkenhagen Structural model selection: Is the chi-square distribution appropriate for likelihood ratio tests? Thursday 15:25-16:50 |
IV-12 Alan Faraj Drug effect of clofazimine on persisting mycobacteria explain an unexpected increase in bacterial load from patients Thursday 15:25-16:50 |
IV-13 Anam Fayyaz Development and Performance Verification of a semi-PBPK Model for Topical Ocular Delivery of Pilocarpine and Timolol to Rabbit Eyes Thursday 15:25-16:50 |
IV-14 Anam Fayyaz Development and Performance Verification of a semi-PBPK Model for Topical Ocular Delivery of Pilocarpine and Timolol to Rabbit Eyes Thursday 15:25-16:50 |
IV-15 Rebekka Fendt Evaluating the benefit of individual patient data for physiologically based pharmacokinetic (PBPK) simulations Thursday 15:25-16:50 |
IV-16 Valentina Fermanelli Correlation structure of Apolipoprotein A4, C3, E kinetics parameters Thursday 15:25-16:50 |
IV-17 Chiara Fornari Importance of stability analysis when using non-linear semi-mechanistic models to describe drug-induced haematotoxicity Thursday 15:25-16:50 |
IV-18 Jose Francis A semi-mechanistic model to characterise the influence of nevirapine- and lopinavir/ritonavir-based therapy on artemether and dihydroartemisinin exposure Thursday 15:25-16:50 |
IV-19 Yu Fu Hemodynamic systems model to characterize cardiovascular drug effects Thursday 15:25-16:50 |
IV-20 Aline Fuchs Assessment of translation of PKPD relationship from animal to human for malaria compounds Thursday 15:25-16:50 |
IV-21 Laura Fuhr Physiologically based pharmacokinetic modeling of the dabigatran antidote idarucizumab Thursday 15:25-16:50 |
IV-22 Masato Fukae Population pharmacokinetic modeling of esaxerenone: a novel nonsteroidal mineralocorticoid receptor blocker Thursday 15:25-16:50 |
IV-23 Fanny Gallais Population pharmacokinetics of ibrutinib and its dihydrodiol metabolite in patients with lymphoid malignancies Thursday 15:25-16:50 |
IV-24 Fiona G. Gao Prediction of human pharmacokinetics of subcutaneously administered insulin formulations Thursday 15:25-16:50 |
IV-25 Kamunkhwala Gausi Pharmacokinetics of isoniazid preventative therapy among HIV-infected pregnant women in high tuberculosis incidence settings Thursday 15:25-16:50 |
IV-26 Sergey Gavrilov Longitudinal assessment of tumor size and neutrophil count in multivariate joint models are more predictive of survival than their baseline values in patients with non-small cell lung cancer Thursday 15:25-16:50 |
IV-27 Peter Gennemark Determination of antisense oligonucleotide tissue half-life Thursday 15:25-16:50 |
IV-28 Eva Germovsek A time-to-event model relating integrated craving to risk of smoking relapse across different nicotine replacement therapy formulations Thursday 15:25-16:50 |
IV-29 Bill Gillespie Torsten: Stan functions for pharmacometric applications. New functionality including within chain parallel computation. Thursday 15:25-16:50 |
IV-30 Anais Glatard Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin levels using PK/PD modeling Thursday 15:25-16:50 |
IV-31 Ferran Gonzalez Pharmacokinetic model development for total and free vancomycin in critically ill children Thursday 15:25-16:50 |
IV-32 Ignacio Gonzalez-Garcia Pharmacokinetic/Pharmacodynamic Modelling of in vivo IL-13 Modulation by a monoclonal antibody (MEDI7836) Thursday 15:25-16:50 |
IV-33 Mario Gonzalez Sales Assembling pharmacometric datasets in R: the puzzle package Thursday 15:25-16:50 |
IV-34 Katharina Martha Götz Predictive Systems Medicine Modelling of Myelosuppression and Recovery of Hematopoietic Cells among Adult Patients with Hematopoietic Cell Transplantation Thursday 15:25-16:50 |
IV-35 Iztok Grabnar Oxcarbazepine and its active metabolite 10-monohydroxycarbamazepine clearance maturation in paediatric patients with epilepsy Thursday 15:25-16:50 |
IV-36 Silvia Grandoni Development and evaluation of a PBPK model to study the pharmacokinetics of inhaled drugs in rats Thursday 15:25-16:50 |
IV-37 Ana-Marija Grisic Semimechanistic clearance models of oncology monoclonal antibodies and impact of study design: cetuximab as a case study Thursday 15:25-16:50 |
IV-38 Jinju Guk Modelling the dose-effect relationship between DAV132, an activated charcoal based product, and fecal concentration of moxifloxacin in healthy volunteers Thursday 15:25-16:50 |
IV-39 Tingjie Guo Exploring practical limitations of model-based Bayesian dose optimization in intensive care patients Thursday 15:25-16:50 |
IV-40 Stefanie Hamacher Population pharmacokinetics of cannabidiol in healthy subjects Thursday 15:25-16:50 |
IV-41 Felix Hammann Population pharmacokinetics and generation of dosing nomograms of daptomycin at a Swiss university hospital Thursday 15:25-16:50 |
IV-42 Lutz Harnisch Dose Selection Process for Younger Children Participating in a Phase 3 Study to Evaluate the Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-occlusive Crisis in Hospitalized Patients With Sickle Cell Disease Thursday 15:25-16:50 |
IV-43 Paul Healy PKPD bridging and extrapolation of efficacy for the use of gabapentin and tramadol in paediatric chronic pain. Thursday 15:25-16:50 |
IV-44 Guenter Heimann An Industry Perspective on Extrapolation in Pediatric Drug Development: A Quantitative Approach to Assess Similarity of Adult and Pediatric Efficacy. Thursday 15:25-16:50 |
IV-45 Farina Hellmann Population pharmacokinetic modelling in Ewing sarcoma patients focussing on etoposide as an example Thursday 15:25-16:50 |
IV-46 Emilie Hénin Therapeutic drug monitoring strategies for Envarsus in de novo renal transplant patients using population modelling and simulations Thursday 15:25-16:50 |
IV-47 Charlotte Kloft Review of NMLE articles published in clinical journals with a higher impact factor Thursday 15:25-16:50 |
IV-48 Thomas Henthorn A population pharmacokinetic model of dense delta-9-tetrahydrocannabinol (THC), 11-OH-THC, and THCCOOH data and its use to estimate daily exposure in an observational cannabis study with sparse data Thursday 15:25-16:50 |
IV-49 Lukas Kovar Physiologically-based pharmacokinetic (PBPK) modelling of nicotine and its main metabolite cotinine in healthy volunteers and smokers Thursday 15:25-16:50 |
IV-50 Anneke Himstedt Prediction of pulmonary exposure based on plasma pharmacokinetics: A comparison of different model-based approaches. Thursday 15:25-16:50 |
IV-51 Richard Höglund Multidrug-resistant genotypes are associated with therapeutic failure of antimalarial therapy in Cambodia; a pharmacometric approach Thursday 15:25-16:50 |
IV-52 Nick Holford Rational dosing of caffeine using target concentration intervention to improve treatment of apnea of prematurity Thursday 15:25-16:50 |
IV-53 Chih-hsuan Hsin Impact of intestinal and renal membrane transporter ABCB1 gene polymorphisms on the pharmacokinetics of digoxin in healthy Caucasian subjects Thursday 15:25-16:50 |
IV-54 Ka Ho, Matthew Hui Evaluation of Parameter Estimation when Fitting a Mixture Model with Covariate Effects using NONMEM Thursday 15:25-16:50 |
IV-55 Ziad Hussein Population Pharmacokinetics of Lemborexant, a Dual Orexin Receptor Antagonist, in Healthy Adult and Elderly Subjects and Subjects with Primary Insomnia Thursday 15:25-16:50 |
IV-56 Eman Ibrahim Obesity and NAFLD activity score increase rate of fibrosis progression in a continuous-time Markov modelling of fibrosis progression in a long-term follow-up biopsy NAFLD cohort. Thursday 15:25-16:50 |
IV-57 Hiroyuki Iida Modelling the biomarker-driven tumour growth inhibition by a novel pan-Trk inhibitor ONO-7579 in xenografted mice Thursday 15:25-16:50 |
IV-58 Luis Ilia Quantitative comparison of in vitro and in vivo variability of microdialysis experiments using nonlinear mixed-effects modelling on the example of linezolid Thursday 15:25-16:50 |
IV-59 Khalid Iqbal Modelling tissue pharmacokinetics: A comparison of empiric and mechanistic PBPK modelling approaches of different complexity exemplified with moxifloxacin Thursday 15:25-16:50 |
IV-60 Itziar Irurzun-Arana ACESO (A Cancer Evolution Simulation Optimizer) Thursday 15:25-16:50 |
IV-61 Kris Oliver Jalusic Pharmacokinetics of vancomycin in the cerebrospinal fluid in critically ill patients Thursday 15:25-16:50 |
IV-62 Petra Jauslin Modeling bounded scales for evaluation of treatment response to subcutaneous nemolizumab in moderate to severe atopic dermatitis Thursday 15:25-16:50 |
IV-64 Jin Jin Model-informed artificial intelligence (AI) solution enabling real-time predictions: towards next generation modeling Thursday 15:25-16:50 |
IV-65 Mats Jirstrand A challenge model of TNFα turnover with LPS provocations and drug intervention Thursday 15:25-16:50 |
IV-66 Curtis Johnston M-EASE-2: A Modelling and simulation study conducted to further characterize the efficacy of low-dose Empagliflozin as Adjunctive to inSulin thErapy (M-EASE) in Type 1 Diabetes Mellitus (T1DM) Thursday 15:25-16:50 |
IV-67 Daniel Jonker The impact of septic shock on the pharmacokinetics and pharmacodynamics of selepressin Thursday 15:25-16:50 |
IV-68 Felix Jost Application of a feedback optimal control algorithm to a population pharmacokinetic-pharmacodynamic model of cytarabine-derived and lenograstim-reduced myelosuppression in acute myeloid leukemia Thursday 15:25-16:50 |
IV-69 Fabian Jung Simulation of the environmental exposure to fenofibrate nanomaterials based on in vitro- and in silico methods Thursday 15:25-16:50 |
IV-70 Wannee kantasiripitak A population pharmacokinetic and exposure-response model of golimumab for targeting endoscopic remission in patients with ulcerative colitis Thursday 15:25-16:50 |
IV-71 Evangelos Karakitsios A methodology to estimate population pharmacokinetic parameters from aggregate concentration-time data and its application to gevokizumab. Thursday 15:25-16:50 |
IV-72 Vangelis Karalis An In Vitro – In Vivo Simulation Methodology for Predicting the Outcome of Bioequivalence Studies Thursday 15:25-16:50 |
IV-73 Eleni Karatza Investigation of the impact of population parameters describing gastric emptying on bioequivalence metrics Thursday 15:25-16:50 |
IV-74 Tatiana Karelina Amyloid β in vitro prion properties and in vivo pathology exacerbation mechanisms studied by translation quantitative systems pharmacology model for prediction of anti-protofibril immunotherapy effects Thursday 15:25-16:50 |
IV-75 Adrien Tessier Use of mixture models in pharmacometric model-based analysis of confirmatory trials: part I - simulation study evaluating type I error and power of proof-of-concept trials Thursday 15:25-16:50 |
IV-76 Hidefumi Kasai Tumor Response Index (TRI): model-based prediction of tumor response and survival in metastatic colorectal cancer patients treated by mFOLFOX6 with bevacizumab Thursday 15:25-16:50 |
IV-77 Takayuki Katsube Evaluation of Variance-based Global Sensitivity Analysis for Covariate Effects Thursday 15:25-16:50 |
IV-78 Aida Kawuma Dolutegravir pharmacokinetics in co-administration with rifampicin. Thursday 15:25-16:50 |
IV-79 Ron Keizer Continuous learning in model-informed precision dosing: a case study Thursday 15:25-16:50 |
IV-80 Zackary Kenz Inflammation and Fibrosis in Nonalcoloholic Steatohepatitis (NASH) Characterized by a Mathematical Model Thursday 15:25-16:50 |
IV-81 Yun Kim A population pharmacokinetic/pharmacodynamic analysis of rosuvastatin according to OATP1B1 and BCRP polymorphisms in young and elderly subjects Thursday 15:25-16:50 |
IV-82 NaYoung Kim Development of predictive model for acute kidney injury after minimally invasive partial nephrectomy Thursday 15:25-16:50 |
IV-83 Seoyoung Kim Population Pharmacokinetic-Pharmacodynamic Modeling of Escitalopram in Patients with Obsessive-Compulsive Disorder Using Yale-Brown Obsessive Compulsive Scale Thursday 15:25-16:50 |
IV-84 Dohyun Kim Optimization of dosing strategy for Colistin using population pharmacokinetic model based on the Bayesian inference Thursday 15:25-16:50 |
IV-85 Lena Klopp-Schulze Exposure-response analyses of the bifunctional fusion protein bintrafusp alfa (M7824) in early drug development Thursday 15:25-16:50 |
IV-86 Franziska Isabelle Kluwe Model-based characterisation of nonlinear voriconazole pharmacokinetics following two different routes of administration Thursday 15:25-16:50 |
IV-87 Lisa Alina Kneller Impact of Cytochrome P450 2D6, -3A4 and P-glycoprotein on Risperidone’s and 9-Hydroxyrisperidone’s plasma concentrations using a whole-body PBPK approach Thursday 15:25-16:50 |
IV-88 Stephan Koehne-Voss A comparison of relative exposure estimates from single trough, multiple trough, and full population PK sampling designs Thursday 15:25-16:50 |
IV-89 Galina Kolesova Application of different approaches to generate virtual patient populations for QSP model of Physiologically based pharmacokinetic model of anti-PD-1 therapeutic antibodies Thursday 15:25-16:50 |